In ALS patients, blood percentage of Tregs inversely correlated with progression rate, and FoxP3 levels were early predictors of ALS progression and survival.[8] Thus, Tregs may be considered important therapeutic targets in ALS addressed by Rapamycin. This evidence concerns the gene FOXP3 and amyotrophic lateral sclerosis.